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A multi-center retrospective chart-review study of MS patients conducted in United 
Kingdom (UK), France (FR), Germany (DE), Italy (IT), Spain (SP) and US to collect 
de-identified data on diagnosis, clinical status and DM approaches. Health care 
providers (HCPs; 95% neurologists) were screened for duration of practice (> = 3yrs) 
and patient volume (> = 15 MS patients/month) and recruited from a large panel to be 
geographically representative in each country. Medical charts of next 10 consecutive 
MS patients were selected by each physician. Results: A total of 3490 eligible MS 
patient charts were abstracted by 360 HCPs (mean age:47yrs; female: 31%; mean 
practice duration:18yrs; mean # of patients seen per month:63; % working in spe-
cialty MS clinic:45%). Patient mean age: 39yrs; female: 66%; top-5 comorbidities: 
depression (14%), anxiety (10%), hypertension (8%), obesity (7%), migraine/headache 
(6%). Tests used by physicians to diagnose MS varied between the countries (UK/
FR/DE/IT/SP/US: %): History/Neurological exam – 79/88/99/95/97/88, Gadolinium 
MRI – 56/93/66/93/96/89, T1 MRI – 49/89/80/84/93/74, T2 MRI – 65/89/66/91/94/82, 
CSF analysis – 51/82/71/3/90/56, Evoked potentials – 34/48/65/77/80/29. Patients 
with moderate/severe disease and currently on disease modifying treatments 
(DMTs) varied (UK/FR/DE/IT/SP/US: %): 50/45/37/58/50/47 & 52/71/75/77/73/78; cor-
respondingly, tests used by physicians to assess MS disease progression/activity 
also varied between the countries (UK/FR/DE/IT/SP/US: %): EDSS–63/83/84/91/92/40, 
Neurological exam–81/91/88/89/84/86, Gadolinium MRI–33/69/36/90/68/70, T1 MRI–
21/53/53/76/54/54, T2 MRI–29/62/41/89/63/65, Ambulation index–9/13/9/24/16/19, 
Brain atrophy–4/14/6/23/15/18, Nine hole peg test–6/3/10/5/3/1 and PASAT–
1/0/12/5/4/1. ConClusions: UK physicians appear to under-utilize the tests to 
diagnose/manage MS patients, whereas physicians in Spain often used them more 
frequently. Observed trends were not correlated to the patient disease severity 
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objeCtives: Differences in compliance and persistence between Parkinson’s dis-
ease (PD) drugs were found in a previous US claim database analysis. The objective 
was to apply the same methodology in another setting using the Clinical Practice 
Research Datalink (CPRD) in the UK. Methods: A retrospective analysis of patients 
starting a new PD drug (rasagiline, selegiline, pramipexole, ropinirole, entacapone, 
tolcapone, levodopa) between January 2009 and January 2012 was conducted using 
CPRD. Patients were categorized as naive to PD therapy (NT) or having prior PD 
therapy (PT), depending on the prescription of other PD drugs within a 12-month 
look-back period. The observation period was 12 months. Compliance was measured 
using the medication possession ratio (MPR) and non-compliance was defined as 
an MPR≤ 80%. Persistence was measured as the duration (days) of uninterrupted 
therapy without gap higher than 45 days. Results: Of the 4,784 patients included 
in the compliance analysis, 3,675 patients (76.8%) had compliance rates > 80%. Mean 
MPRs were generally comparable across PD products (range:84%-90%, all pairwise 
p= NS). Percentage of patients with MPR> 80% was significantly greater with rasagil-
ine (85.6%, all p< 0.05 except vs. ropinirole p= NS). Of the 5,266 patients included in 
the persistence analysis, the highest mean number of persistent days of treatment 
was reported for rasagiline (284 days; all p< 0.05 vs others, except vs. ropinirole 
p= 0.14 and levodopa p= 0.06). Patient persistence at 12 months was significantly 
greater with rasagiline compared with others in NT patients (66.5%, all p< 0.05) 
scenarios even though that the additional clinical benefit profile was uncertain and 
pricing not optimal. When developing potential budget estimates based on sample 
size and complexity of a clinical trial for motor fluctuations or dyskinesias as pri-
mary endpoint a significant clinical benefit was highly likely and premium pricing 
possible. However, a positive investment decision was uncertain due to the high 
development cost. ConClusions: Even though there are incentives to add patient 
relevant endpoints in the development programmes the return on investment could 
potentially not be high enough for a positive investment decision. Target profiling 
including market access and pricing outcomes could optimize investment decisions.
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objeCtives: To assess clinical characteristics of MS patients not on any DMTs in key 
countries in European Union (EU) and the U.S. Methods: A multi-country multi-
center medical chart-review study of MS patients was conducted in 4Q2012 among 
Health care providers (HCPs; > 85% neurologists) in hospitals and private practices 
to collect de-identified data. HCPs from UK, Germany, France, Italy and Spain (5EU) 
and the US were screened for duration of practice (> = 3yrs) and patient volume 
(> = 15 MS patients/month) and recruited from a large panel to be geographically 
representative in each country. Medical charts of next 10 consecutive MS patients 
were completed by each physician. HCPs abstracted patient diagnosis, treatment 
patterns and patient symptomatology/disease status. MS patients not on any 
DMTs were analyzed. Results: A total of 967 eligible MS patients were included 
in the analysis (5EU:749; US:218). Mean age (yrs) – 5EU:39.0yrs, US:42.2yrs; Female – 
5EU:69%; US:67%. Key reasons for not receiving DMTs were (5EU/US): mild/early-MS 
(35%/36%), patient refusal (26%/44%), progressive/severe/advanced-MS (20%/17%), 
lack of efficacy of current treatment options (10%/14%), side-effects/tolerance/co-
morbidities (6%/12%), waiting for DMTs to become available (5%/12%) and funding/
authorization/guidelines (4%/7%). Among patients who refused DMTs, more than 
half were not convinced of therapy benefits. Distribution of MS type was (5EU/US): 
Clinically Isolated Syndrome (CIS)-26%/25%, Relapse Remitting MS (RRMS)-44%/49% 
and Secondary Progressive MS (SPMS)-30%/26%. Patients with moderate/severe dis-
ease and those with active/highly active disease (both, per physician judgment) 
were (5EU/US): CIS:10%/11%, RRMS:25%/40%, SPMS:95%/86%, and CIS:31%/44%, 
RRMS:39%/37%, SPMS:36%/32% respectively. Mean Expanded Disability Status Scale 
score were (5EU/US): CIS:0.8/0.7, RRMS:1.8/2.2, SPMS:6.5/5.6); % patients currently 
suffering a relapse were (5EU/US): CIS:20%/29%, RRMS:21%/15%, SPMS:6%/16%; 
% patients with > = 1 relapses in last 12months were (5EU/US): CIS:69%/69%, 
RRMS:52%/58%, SPMS:18%/32%. ConClusions: Among MS patients not on any 
DMTs, disease burden seems substantial. Further research is warranted to scrutinize 
the observed patient management practices to alleviate patient burden.
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objeCtives: To assess disease burden of SPMS patients treated with DMTs in 
EU and the U.S. Methods: A multi-country chart-review study of SPMS patients 
was conducted among neurologists in hospitals/private practices to collect de-
identified data. Neurologists from UK/Germany/France/Italy/Spain (5EU) and 
US were screened for practice-duration (> = 3yrs) and patient-volume (> = 15MS 
patients/month) and recruited from a large panel to be geographically representa-
tive in each country. Charts of next 2 consecutive SPMS patients were selected 
by each neurologist. Neurologists abstracted patient diagnosis, treatment pat-
terns and patient symptomatology/disease status. SPMS patients on DMTs were 
analyzed. Results: In 4Q2012, 360 Neurologists (5EU:259; US:101) abstracted 699 
eligible SPMS patient charts (5EU:497; US:202); 420 (5EU:274; US:146) patients were 
managed with DMTs. Mean age – 5EU:46.5yrs, US:49.2yrs; Female – 5EU:58%; US:66%. 
Mean time-to-1st DMT initiation (5EU/US; months) from diagnosis was 21/27; cur-
rent DMT patterns (5EU/US) were: 1st line (25%/34%), 2nd line (39%/38%) & 3rd+ 
line (36%/28%). Interferon beta-1b (5EU) and glatiramer acetate (US) were predomi-
nantly observed in 1st/2nd line; fingolimod and natalizumab use was observed 
in 2nd-line but they dominated later lines. Mean time-to-1stDMT initiation (5EU/
US: months) from diagnosis (1st:45/35, 2nd:13/30, 3rd+:12/10) and mean treatment 
time (5EU/US: months) on current 1st (85/91), 2nd (38/35; prior 1st line: 57/48) and 
3rd+ line (19/24; prior 2nd line: 35/46) differed. Patients with severe disease and 
those with active/highly active disease (both, per physician judgment) were (5EU/
US): 1st:15%/20%, 2nd:20%/18%, 3rd+:35%/37% and 1st:45%/61%, 2nd:63%/73%, 
3rd+:57%/68% respectively; mean Expanded Disability Status Scale scores also dif-
fered (5EU/US): 1st:5.1/5.0, 2nd:5.6/5.5, 3rd+:5.8/6.1. ConClusions: Among SPMS 
patients currently managed with DMTs, the disease burden increased as the line 
of treatment increased, both in 5EU and the US. Patients in 2nd/3rd+line of treat-
ments had progressed through earlier line(s) of treatment quickly. Further research 
is warranted to scrutinize the effectiveness of therapeutic options and sequencing 
strategies to alleviate patient burden.
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objeCtives: To assess the patterns of use of tests to diagnose and assess disease 
progression/activity in MS in the European Union and United States (US). Methods: 
